科学研究表明：埃プ斯坦-巴尔病毒（EBV）在某些肿瘤疾病的发展中扮演着关键角色。因此，本研究旨在通过基于病毒外壳蛋白及核蛋白免疫原（EBNA）表位设计有效的疫苗，以控制该病毒的致病性。目前，还没有有效的药物或疫苗来治疗或预防EBV感染。因此，我们运用基于计算机的策略设计表位疫苗。我们使用基于计算机的策略，设计出了一种强有力的多表位肽疫苗，用于对抗EBV。该疫苗由来自两种不同病毒株中的三种不同蛋白质（外壳、外壳、EBNA）中的844个氨基酸组成。这些表位具有高免疫原性，不太可能引起过敏反应。为了增强疫苗的免疫原性，我们使用rOv-ASP-1作为佐剂，并将其连接到疫苗的N和C端。我们评估了疫苗结构的物理化学和免疫学性质。根据生物信息学预测，所提出的疫苗结构稳定，稳定指数为33.57，pI为10.10。对接分析显示，疫苗蛋白能够正确地与免疫接受体结合。我们的结果表明，多表位疫苗可能具有潜在的免疫原性，并诱导对EBV的体液和细胞免疫反应。该疫苗能够适当地与免疫接受体相互作用，同时具有高质量的结构和合适的特性，如高稳定性。版权所有©2023 Larijani，Kia-Karimi和Roostaei。

Scientific findings have shown that Epstein-Barr virus (EBV) plays a key role in the development of some tumor diseases. Therefore, this study intends to take a practical step in controlling the pathogenicity of this virus by designing an effective vaccine based on the virus Capsid Envelope and Epstein-Barr nuclear immunogen (EBNA) Proteins Epitopes. Currently, there are no effective drugs or vaccines to treat or prevent EBV infection. So, we applied a computer-based strategy to design an epitope vaccine.We designed a powerful multi-epitope peptide vaccine against EBV using in silico analysis. The vaccine is made up of 844 amino acids derived from three different types of proteins (Envelope, Capsid, EBNA) found in two different viral strains. responses. These epitopes have a high immunogenic capacity and are not likely to cause allergies. To enhance the vaccine immunogenicity, we used rOv-ASP-1, a recombinant Onchocerca volvulus activation associated protein-1, as an adjuvant and linked it to the vaccine's N and C terminus. The physicochemical and immunological properties of the vaccine structure were evaluated. The proposed vaccine was stable, with a stability index of 33.57 and a pI of 10.10, according to bioinformatic predictions. Docking analysis revealed that the vaccine protein binds correctly with immunological receptors.Our results demonstrated that the multi-epitope vaccine might be potentially immunogenic and induce humoral and cellular immune responses against EBV. This vaccine can interact appropriately with immunological receptors Also, it has a high-quality structure and suitable characteristics such as high stability.Copyright © 2023 Larijani, Kia-Karimi and Roostaei.